PCI Biotech Holding ASA

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing new technologies and novel therapies through its photochemical technology platform. The company, founded in 2007, is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker PCIB. With a small team based at the Oslo Cancer Cluster Innovation Park, PCI Biotech is at the forefront of innovation in the biopharmaceutical industry.

The company's technology platform is currently under development in two key areas. Firstly, the Photochemical lysis (PCL) technology aims to increase yield and reduce impurities in gene therapy (viral vector) manufacturing. Secondly, the Photochemical internalization (PCI) technology seeks to induce light-triggered endosomal release, potentially unlocking the potential of a wide array of modalities.

While specific information about the industries targeted and the latest investment is currently unavailable, PCI Biotech Holding ASA presents an intriguing opportunity for investors looking to support advancements in biopharmaceutical technology and innovative therapies. For further details, interested parties can visit the company's website www.pcibiotech.com or reach out to them at Ullernchausséen 64, N-0379 Oslo.